Health Catalyst Future Growth
Future criteria checks 1/6
Health Catalyst is forecast to grow earnings and revenue by 39.5% and 8.5% per annum respectively. EPS is expected to grow by 58.5% per annum. Return on equity is forecast to be 15.6% in 3 years.
Key information
39.5%
Earnings growth rate
58.5%
EPS growth rate
| Healthcare Services earnings growth | 27.6% |
| Revenue growth rate | 8.5% |
| Future return on equity | 15.6% |
| Analyst coverage | Good |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Benign Growth For Health Catalyst, Inc. (NASDAQ:HCAT) Underpins Its Share Price
Apr 04
Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible
Mar 09Health Catalyst Looks To Slim Down As It Faces Industry Headwinds (Downgrade)
Feb 16Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jan 27What Health Catalyst, Inc.'s (NASDAQ:HCAT) 25% Share Price Gain Is Not Telling You
Dec 24Is Health Catalyst, Inc. (NASDAQ:HCAT) Trading At A 47% Discount?
Dec 15Is Health Catalyst (NASDAQ:HCAT) Weighed On By Its Debt Load?
Oct 24Subdued Growth No Barrier To Health Catalyst, Inc.'s (NASDAQ:HCAT) Price
Jul 31Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Jun 27Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Feb 22Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 22% Above Their Intrinsic Value Estimate
Dec 06Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Nov 03Health Catalyst: Looking For A Turnaround For This 'Bio Boom' Candidate
Oct 14Health Catalyst names Kevin Freeman as Chief Growth Officer, Tarah Bryan as Chief Marketing Officer, Dave Ross as Chief Technology Officer
Sep 07Health Catalyst Non-GAAP EPS of -$0.03 beats by $0.07, revenue of $70.63M beats by $0.75M
Aug 04Is Health Catalyst (NASDAQ:HCAT) A Risky Investment?
Jul 26Is Health Catalyst (NASDAQ:HCAT) Using Debt In A Risky Way?
Apr 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 391 | -51 | -1 | 50 | 4 |
| 12/31/2025 | 345 | -55 | -8 | 31 | 16 |
| 12/31/2024 | 309 | -63 | -5 | 14 | 16 |
| 12/31/2023 | 296 | -118 | -47 | -33 | N/A |
| 9/30/2023 | 290 | -124 | -44 | -29 | N/A |
| 6/30/2023 | 285 | -147 | -61 | -44 | N/A |
| 3/31/2023 | 282 | -148 | -59 | -42 | N/A |
| 12/31/2022 | 276 | -137 | -53 | -35 | N/A |
| 9/30/2022 | 272 | -151 | -47 | -30 | N/A |
| 6/30/2022 | 265 | -145 | -40 | -24 | N/A |
| 3/31/2022 | 254 | -147 | -34 | -19 | N/A |
| 12/31/2021 | 242 | -153 | -42 | -23 | N/A |
| 9/30/2021 | 230 | -147 | -39 | -17 | N/A |
| 6/30/2021 | 216 | -135 | -36 | -17 | N/A |
| 3/31/2021 | 200 | -126 | -29 | -13 | N/A |
| 12/31/2020 | 189 | -115 | -37 | -26 | N/A |
| 9/30/2020 | 179 | -86 | -39 | -35 | N/A |
| 6/30/2020 | 171 | -99 | -41 | -36 | N/A |
| 3/31/2020 | 165 | -181 | -48 | -44 | N/A |
| 12/31/2019 | 155 | -241 | -37 | -32 | N/A |
| 9/30/2019 | 148 | -304 | -37 | -32 | N/A |
| 6/30/2019 | 141 | -282 | -37 | -33 | N/A |
| 3/31/2019 | 127 | -190 | -41 | -38 | N/A |
| 12/31/2018 | 113 | -114 | -43 | -40 | N/A |
| 12/31/2017 | 73 | -59 | -40 | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HCAT's revenue (8.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: HCAT's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HCAT's Return on Equity is forecast to be low in 3 years time (15.6%).